navoximod
oral IDO1 inhibitor Ph. I completed (50-800 mg) for cancer from phenylimidazole + SBDD JPET, April 14, 2023 NewLink Genetics / Genentech
Molecules of the Month - April 2023
5 minute read
May 29, 2023
Navoximod: An Early Heme-Binding Inhibitor of the Once Red-Hot Immunotherapy Target, IDO1